5 Stocks That Were On Jim Cramer’s Radar As He Discussed AI

Page 4 of 4

1. Johnson & Johnson (NYSE:JNJ)

Number of Hedge Fund Holders In Q2 2025: 95

Johnson & Johnson (NYSE:JNJ) is one of the most diversified healthcare companies in the world. The firm operates in the pharmaceutical, medical devices, and other industries. Cramer previously discussed the stock on September 11th, when he wondered whether the major “litigation overhang” surrounding the firm actually involved an “overplayed” hand by the plaintiffs’ lawyers. This time, he was full of praise for Johnson & Johnson (NYSE:JNJ)’s cancer portfolio:

“Well tonight we got JNJ and it’s incredibly important because Joaquin, he does not, he does not do a lot of, he does no interviews, frankly. And I think this is a terrific time because we also have. Look, they’re spending more than 50 billion. I think that they are really at the forefront of building in America. Other than Eli Lilly. So I want to ask about that. Other than that, the stuff that they’re doing against cancer. It’s so incredible. I think we gotta talk about that. I think they are now ahead of everyone, in terms of trying to cure cancer. And I don’t use that word lightly because my ma died of cancer in a horrible fashion, and it’s a cancer that’s been cured since then.”

While we acknowledge the potential of JNJ to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than JNJ and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Page 4 of 4